Apr 19, 2019 - These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Apr 18, 2019 - Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apr 17, 2019 - Key highlights of the past week are collaborations and pipeline updates.
Apr 16, 2019 - The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Apr 15, 2019 - Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
Apr 15, 2019 - Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Apr 08, 2019 - Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.
Apr 08, 2019 - Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.